ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
Mar 09, 2018 12:01 pm UTC| Business
-- Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing Authorization application -- --...
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
Mar 09, 2018 12:01 pm UTC| Business
Pipeline Achievements in 2017 Included Progress with Three Phase 3 and Two Phase 2 Clinical Trials -Key 2018 Clinical Milestones Anticipated for All Three Development Compounds Lead Compound OBE2109...
Trillium Therapeutics Reports Annual 2017 Financial and Operating Results
Mar 09, 2018 12:00 pm UTC| Business
Presented evidence of clinical activity and good tolerability from both TTI-621 trials at ASHReceived FDA clearance to proceed with second clinical CD47 program, TTI-622Cash and marketable securities of $81.8 million at...
Mar 09, 2018 12:00 pm UTC| Business
CANTON, Mass., March 09, 2018 -- Destination XL Group, Inc. (NASDAQ:DXLG), the largest omni-channel specialty retailer of big tall men's apparel, announced today it will release its fourth quarter and fiscal 2017...
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
Mar 09, 2018 12:00 pm UTC| Business
FREMONT, Calif., March 09, 2018 -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with...
Cortado Server 9.0 Enhances Features for Secure Management of Mobile Productivity
Mar 09, 2018 12:00 pm UTC| Business
BERLIN, Germany and DENVER, Colo., March 09, 2018 -- Cortado Mobile Solutions today announces a new version of its enterprise mobility solution, Cortado Server 9.0. The latest version comes with numerous security and...
MacroGenics to Present at Cowen Health Care Conference
Mar 09, 2018 12:00 pm UTC| Business
Rockville, MD, March 09, 2018 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the...